TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BCAL Diagnostics Limited ( (AU:BDX) ) just unveiled an update.
BCAL Diagnostics Limited has achieved a significant milestone with the commercial launch of BREASTESTplus™, a world-first diagnostic test designed for the early detection of breast cancer. The company is navigating the challenges of market entry, focusing on expanding its market presence and scaling revenue generation. BCAL is also advancing its early-detection programs for ovarian and pancreatic cancers, aiming to diversify its revenue streams and enhance its clinical utility. A $10 million convertible note facility is being considered to support these efforts, with $5 million already committed, ensuring the company’s operational sustainability and market expansion.
The most recent analyst rating on (AU:BDX) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is a healthcare company transitioning from a research and development organization to a commercial entity. It focuses on developing diagnostic products, with a primary emphasis on early cancer detection, notably breast cancer, through its innovative product BREASTESTplus™.
Average Trading Volume: 461,292
Technical Sentiment Signal: Buy
Current Market Cap: A$33.1M
Find detailed analytics on BDX stock on TipRanks’ Stock Analysis page.